US court rejects Glenmark's patent plea for Finacea
The companies had filed a case against Glenmark in 2013 after it had filled an Abbreviated New Drug Application seeking to market a generic azelaic acid hydrogel in 2012.
PTI New York Last Updated: July 29, 2015 | 12:48 IST
(Pic for representation purpose only. Source: Reuters)
Drug firm Glenmark's patent plea for generic skin care drug has been rejected by a US court saying that it infinges upon the patent of Bayer Healthcare.
The US District Court of Delaware at Wilmington, has said that claims of Bayer Healthcare Pharmaceuticals Inc, Intendis and Intraserv's litigation for Bayer's Finacea, a gel for treating the common skin condition rosacea against Glenmark is valid.
The court came to the conclusion that Glenmark had infringed the "070 patent" of the plaintiffs and "that asserted claims of 070 patents are valid "and ordered the judgement in favour of Bayer and other plaintiffs.
The companies had filed a case against Glenmark in 2013 after it had filled an Abbreviated New Drug Application (ANDA) seeking to market a generic azelaic acid hydrogel in 2012.
Bayer Healthcare Pharmaceuticals Inc is the holder of approved New Drug Application for Finacea gel.
Glenmark currently employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries and has 6 R&D centres.